1. Home
  2. EPSN vs CRDF Comparison

EPSN vs CRDF Comparison

Compare EPSN & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Epsilon Energy Ltd.

EPSN

Epsilon Energy Ltd.

N/A

Current Price

$5.61

Market Cap

132.1M

Sector

Energy

ML Signal

N/A

Logo Cardiff Oncology Inc.

CRDF

Cardiff Oncology Inc.

N/A

Current Price

$2.01

Market Cap

130.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
EPSN
CRDF
Founded
2005
1999
Country
Canada
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
132.1M
130.7M
IPO Year
2018
2012

Fundamental Metrics

Financial Performance
Metric
EPSN
CRDF
Price
$5.61
$2.01
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$9.63
AVG Volume (30 Days)
192.1K
678.6K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
4.39%
N/A
EPS Growth
N/A
27.37
EPS
0.30
N/A
Revenue
N/A
$365,993.00
Revenue This Year
$41.35
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$18.95
N/A
Revenue Growth
N/A
49.61
52 Week Low
$4.20
$1.48
52 Week High
$8.50
$4.56

Technical Indicators

Market Signals
Indicator
EPSN
CRDF
Relative Strength Index (RSI) 68.41 54.74
Support Level $5.33 $1.99
Resistance Level $6.49 $2.05
Average True Range (ATR) 0.19 0.13
MACD 0.07 0.06
Stochastic Oscillator 71.30 92.08

Price Performance

Historical Comparison
EPSN
CRDF

About EPSN Epsilon Energy Ltd.

Epsilon Energy Ltd is engaged in the acquisition, development, gathering, and production of natural gas and oil reserves. The operating segments of the company include Upstream segment activities including acquisition, development, and production of natural gas reserves on properties within the United States. The Gas Gathering segment partners with two other companies to operate a natural gas gathering system, and the corporate segment activities include corporate listing and governance functions of the corporation. The company generates revenue from the sale of crude oil and natural gas.

About CRDF Cardiff Oncology Inc.

Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.

Share on Social Networks: